Pharmafile

FEBRUARY 22, 2023

Published date: 22/02/2023 Summary: - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - London, UK, 22nd February, 2023 -- PTC Therapeutics, Ltd. Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can walk.

52

52

European Pharmaceutical Review

MAY 18, 2023

The therapy is the first janus kinase (JAK) inhibitor that will be available for treatment of Crohn’s disease in England and Wales, AbbVie said. Crohn’s disease is a chronic condition and is estimated to affect over 155,000 adults in the UK. “As It is taken as a once-daily pill.

Immunity 80

Immunity Immunization Hospitals 80

European Pharmaceutical Review

OCTOBER 26, 2022

Gedeon Richter UK Ltd has announced that the UK National Institute for Health and Care Excellence (NICE) has recommended the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults of reproductive age with moderate-to-severe symptoms of uterine fibroids on the National Health Service (NHS) in England and Wales.

81

81

European Pharmaceutical Review

FEBRUARY 20, 2023

According to a new report on UK life sciences recruitment, there were 11,200 new professional scientific vacancies in the industry across England and Wales in 2022. The volume of new professional scientific vacancies in the life sciences industry across England and Wales in 2022 constituted a year-on-year decrease of 15.6

Clinic Management 74

Clinic Management Vaccines 74

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. Epilepsy affects more than 600,000 people in the UK and for some, seizures can be life-threatening.

Documentation 94

Documentation 94

European Pharmaceutical Review

FEBRUARY 29, 2024

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. She emphasised this recommendation is significant because DVCd “has been available in Scotland and Northern Ireland since 2022”.

Documentation 99

Documentation Pharmaceutical Companies Pharmaceutical Companies 99

Pharmaceutical Business Review

SEPTEMBER 17, 2023

Once NICE’s final technology appraisal is released, daridorexant will become the first dual orexin receptor antagonist (DORA) to be prescribed through the NHS in England and Wales.

98

98

Pharmaceutical Technology

AUGUST 19, 2022

The UK National Institute for Health and Care Excellence (NICE) has r ecommended Vifor Fresenius Medical Care Renal Pharma’s Tavneos (avacopan) plus rituximab or cyclophosphamide to treat adults with two ANCA-associated vasculitis (AAV) forms. Vifor anticipates launching Tavneos in the country in the coming weeks.

52

52

pharmaphorum

FEBRUARY 25, 2021

The rare disease community has a golden opportunity to transform the way care is delivered across all four UK nations – that’s according to speakers at a parliamentary reception held to mark 2021’s Rare Disease Day. The framework is a UK-wide commitment from the four nations to make progress on these priorities.

Documentation 93

Documentation Labelling 93

European Pharmaceutical Review

OCTOBER 13, 2022

Health Technology Wales. All Wales Therapeutics & Toxicology Centre. Agencies from the UK, Canada and Australia will seek opportunities to improve HTA and regulatory relationships. In addition to NICE, the bodies involved are: Canadian Agency for Drugs and Technologies in Health (CADTH). Healthcare Improvement Scotland.

Communication 82

Communication 82

pharmaphorum

APRIL 6, 2021

A new organisation dedicated to increasing the use of digital health in the NHS in Wales has come into being, 18 months after the move was first unveiled by the Welsh government. . One key issue was that it was sometimes challenging for the NWIS to participate in audits and investigations across all four UK nations.

Documentation 59

Documentation Vaccines 59

Pharmafile

MARCH 28, 2023

Published date: 28/03/2023 Summary: • Tezspire (tezepelumab) is a first-in-class and will be the only biologic medicine to have no phenotype or biomarker limitation for people with severe uncontrolled asthma, aged 12 years and over in England and Wales.[1],[2] read more

40

40

pharmaphorum

JANUARY 27, 2021

A plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today after it was sent a suspicious package. Wockhardt UK in Wrexham this morning received a suspicious package. The safety of our employees and business continuity remain of paramount importance.

Vaccines 98

Vaccines Packaging Hospitals 98

European Pharmaceutical Review

AUGUST 16, 2023

The National Institute for Health and Care Excellence (NICE) has also issued guidance recommending reimbursement of Pombiliti + Opfolda for use within the National Health Service (NHS) in England and Wales. The post UK approval for Pompe Disease therapy appeared first on European Pharmaceutical Review.

81

81

pharmaphorum

APRIL 1, 2022

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high risk of fractures. ” The post NICE ends UK access disparity to osteoporosis drug Evenity appeared first on.

Documentation 59

Documentation 59

pharmaphorum

JULY 15, 2022

The just-published final technology appraisal document recommends that Vazkepa (icosapent ethyl) can be prescribed to people in England and Wales for adult patients with high-risk cardiovascular disease and elevated levels of triglycerides (1.7 mmol/litre or above) in their blood who are already taking statins. mmol/litre.

Documentation 98

Documentation Diabetes 98

pharmaphorum

NOVEMBER 8, 2022

In the UK alone, the disease affects around 8,000 people each year. Previously, there was no immunotherapy treatment option available for people with early stage or locally advanced TNBC, creating an unmet need for these patients,” said David Long, head of oncology at MSD UK. After a median follow-up of 39.1

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

MARCH 30, 2023

A £277 million joint government and industry funding will help four UK life sciences companies to advance life sciences manufacturing projects. The backing will support over 500 jobs at life sciences companies across the UK. This will create 39 new jobs and safeguard a further 37 at its Wrexham facility in North Wales.

Vaccines 73

Vaccines 73

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . There are around 130,000 people with MS in the UK, with 7,000 new diagnoses a year.

Hospitals 111

Hospitals Documentation 111

pharmaphorum

FEBRUARY 4, 2021

For World Cancer Day, David Long, business unit director of Oncology at MSD UK tells pharmaphorum about the company’s ‘Do It Yourself’ campaign launched in the North East to raise awareness of lung cancer symptoms. Poor outcomes in UK. We know this is the third most prevalent cancer in the UK and the biggest killer.

Chemotherapy 133

Chemotherapy Compounding 133

pharmaphorum

MARCH 16, 2021

The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate. New biotech Antiverse has raised seed funding of £1.4

Drug Development 85

Drug Development 85

pharmaphorum

FEBRUARY 16, 2021

UK health chiefs have urged caution over any relaxation of lockdown rules amid signs that the impact of vaccination and social distancing regulations are beginning to work. Around 300 volunteers will take part in the UK trial, with the first vaccinations taking place later in February.

Vaccines 59

Vaccines Hospitals Immunity Immunization 59

pharmaphorum

SEPTEMBER 22, 2022

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL). Second indication coming.

Adverse Reactions 98

Adverse Reactions Documentation Hospitals 98

PharmaShots

MAY 3, 2023

Shots: The NICE has recommended Lupkynis in combination with mycophenolate mofetil for use within NHS England & NHS Wales in adults with active LN class III, IV, or V The recommendation was based on the P-III study (AURORA 1 & 2) evaluating voclosporin + MMF & corticosteroids vs MMF & corticosteroids alone.

40

40

European Pharmaceutical Review

JANUARY 19, 2023

Shelagh McKinlay, Head of Patient Advocacy at Myeloma UK stated: “There aren’t many treatment options for patients in the third-line setting… This regimen also provides patients with an all-oral option that allows them the convenience of receiving their treatment in their own homes.”

Hospitals 73

Hospitals Documentation 73

pharmaphorum

MAY 14, 2021

Concerns are emerging in the UK about the spread of the coronavirus variant that has caused a surge in cases in India, prompting warnings that lockdown easing plans may need a rethink. Latest figures show there are 1,313 cases of the variant in the UK, compared with 520 recorded in the previous week. Known as B.1.6

Vaccines 91

Vaccines Hospitals 91

pharmaphorum

JULY 16, 2021

The UK cost-effectiveness body first turned down Zytiga (abiraterone acetate) for this use in June 2020, but said four months later that it would reconsider its decision. That review has now concluded, and NICE has said it won’t change its mind.

Chemotherapy 52

Chemotherapy Drug Pricing 52

pharmaphorum

NOVEMBER 16, 2022

The health technology assessment (HTA) agency has turned down five other COVID-19 therapies, notably AstraZeneca’s Evusheld (tixagevimab plus cilgavimab) – which patient organisations in the UK have been clamouring for access to, as it is an alternative to vaccinations for some vulnerable patient groups. 5 subvariant.

Vaccines 99

Vaccines Documentation 99

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig was cleared for use by NHS Scotland last year, with Ajovy given a green light in January 2020.

84

84

pharmaphorum

AUGUST 11, 2022

Figures from the UK Office for National Statistics (ONS) have revealed that the number of people with higher levels of COVID-19 antibodies in their blood is declining quickly – leading to calls for booster vaccination campaigns to be started as soon as possible. in March to 71.9% in mid-July. “We already know the latest Omicron BA.4

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig was cleared for use by NHS Scotland last year, with Ajovy given a green light in January 2020.

80

80

pharmaphorum

AUGUST 18, 2022

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos – which will be launched in the next few weeks. The post CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos appeared first on.

Documentation 52

Documentation 52

pharmaphorum

JANUARY 9, 2023

The transaction will be effected by means of a UK scheme of arrangement under Part 26 of the UK Companies Act 2006, subject to approval of Amryt shareholders, sanction by the High Court of Justice of England and Wales, and other customary closings, including regulatory/antitrust approvals.

Drug Development 93

Drug Development 93

pharmaphorum

DECEMBER 21, 2021

The platform is currently powering three in-market rapid LFTs for COVID-19 in the UK, US and Canada. So far, it has raised £350,000 from the Development Bank of Wales, with the rest coming from members of Wealth Club, a high-net-worth investment service.

Customer Service 72

Customer Service 72

pharmaphorum

JUNE 1, 2021

Nerida Scott is the head of Johnson & Johnson Innovation EMEA, based at the Innovation Centre in London, UK. She received her BSc from Sydney University, Australia, and her PhD in Biochemistry as the Prince of Wales’ scholar, Trinity College, Cambridge University, UK. About the author.

Communication 52

Communication 52

European Pharmaceutical Review

DECEMBER 12, 2022

The approval means potentially a further 250,000 patients across the full spectrum of LVEF >40 percent, including HF with reduced, mildly reduced, and preserved ejection fraction (HFrEF, HFmrEF, HFpEF) will be eligible for treatment in England and Wales. AstraZeneca’s oral dapagliflozin drug. 0.97]; p=0.01, ARR 1.5 0.99]; p=0.03, ARR 1.5

Diabetes 101

Diabetes 101

pharmaphorum

AUGUST 16, 2022

The UK’s Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna’s bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults. The UK is the first country to approve use of an Omicron-targeted vaccine. 1 subvariant.

Vaccines 59

Vaccines Immunity Immunization 59